Compare Campbell Soup Co. (CPB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Vertex Pharmaceuticals Incorporated — how do they compare? Campbell Soup Co. trades at $19.4 (market cap $5.64B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 22.7× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays a 5.29% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| CPB | VRTX | |
|---|---|---|
Market Cap | $5.64B | $128.16B |
Volume | 8,200,811 | 806,603 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $557.96 |
52-Week Low | $18.90 | $407.37 |
Typical Hold Time | 98 Days | 120 Days |
Enterprise Value | $12.70B | $122.29B |
Dividend Yield | 5.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $19.37, up 1.95% on the day, with a bearish technical outlook and mixed fundamentals. Recent Q4 2026 earnings missed expectations, while the company implemented a 36% dividend cut and announced a $500 million cost-savings plan. Valuation metrics appear reasonable with P/E of 14.44 and P/S of 0.58, but profit margins have declined from 9.16% in 2023 to 4.13% projected for 2026.
The outlook remains challenging with declining profitability and bearish analyst sentiment, though current valuation may offer value for patient investors. Key risks include ongoing margin pressure, competitive threats, and execution of the turnaround plan. With only 6.9% of analysts rating it Buy, the stock faces significant headwinds despite trading near consensus price target of $19.67.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
